On Dec. 2, 2021, National Resilience and Harvard University announed they had established a five-year research and development alliance with a $30 million commitment from Resilience directed toward the development of complex medicines, including biologics, vaccines, nucleic acids and cell and gene therapies.

Under the alliance agreement coordinated by Harvardﾒs Office of Technology Development (OTD), Resilience was to fund faculty-initiated research focused on certain novel therapeutic and biomanufacturing technologies pioneered in university labs.